Overview: Histoplasma Galactomannan TestIntroduction: The Histoplasma Galactomannan Test detects Histoplasma antigen in urine, serum, or bronchoalveolar lavage to diagnose fungal infection, causing fever or lung issues. Aligned with 2023 IDSA guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, antifungal therapy, and improving outcomes in mycology for patients with suspected histoplasmosis, particularly in severe or disseminated cases.
Other Names: Histoplasma Antigen Assay, Histoplasmosis Galactomannan Test.
FDA Status: Laboratory-developed test (LDT), meeting mycology standards for diagnostic accuracy.
Historical Milestone: Histoplasma antigen testing began in the 1980s with fungal diagnostics. Galactomannan assays improved in the 2000s, enhancing detection in severe cases.
Purpose: Diagnoses histoplasmosis, guides antifungal therapy, and detects Histoplasma antigen in patients with fever or lung issues.
Test Parameters: 1. Histoplasma Galactomannan
Pretest Condition: No fasting required. Collect urine, serum, or bronchoalveolar lavage at any time. Report symptoms like fever, cough, or chest pain, and list medications or travel history.
Specimen: 5-20 mL urine (sterile container), 2-5 mL serum (SST), or 5-10 mL bronchoalveolar lavage (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 2 hours.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fever, cough, chest pain, or travel to Histoplasma-endemic areas. Include current medications, especially antifungals, and immunosuppression status.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for antifungal therapy.
Procedural Considerations: Uses an immunoassay to detect Histoplasma galactomannan antigen. Results are available in 3-5 days, enabling clinical decisions. Performed in laboratories, often for disseminated histoplasmosis.
Factors Affecting Result Accuracy: Improper sample handling or contamination can affect results. Low antigen levels in early infection may yield false negatives.
Clinical Significance: Positive antigen confirms histoplasmosis, guiding antifungal therapy (e.g., amphotericin B). Negative results may require repeat testing in suspected cases.
Specialist Consultation: Consult an infectious disease specialist or pulmonologist for result interpretation and treatment planning.
Additional Supporting Tests: Histoplasma antibody test, fungal culture, or imaging (e.g., chest CT) to confirm histoplasmosis.
Test Limitations: False negatives may occur in early or localized infection. Clinical correlation and confirmatory testing are needed.
References: IDSA Histoplasmosis Guidelines, 2023; Clinical Infectious Diseases, Wheat LJ, 2022.
